Aligos therapeutics announces positive topline results from the phase 2a herald study of alg-055009 for the treatment of mash

South san francisco, calif., sept. 19, 2024 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive topline results from the phase 2a herald study of alg-055009, a thyroid hormone receptor beta (thr-Β) agonist, in metabolic-dysfunction associated steatohepatitis (mash) subjects.
ALGS Ratings Summary
ALGS Quant Ranking